Oncolytics Biotech Inc. (ONCY)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Oncolytics Biotech (ONCY) Loses 8.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Oncolytics Biotech (ONCY) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
All You Need to Know About Oncolytics Biotech (ONCY) Rating Upgrade to Buy
Oncolytics Biotech (ONCY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Oncolytics Biotech Inc. (ONCY) Q1 2025 Earnings Call Transcript
Oncolytics Biotech Inc. (NASDAQ:ONCY ) Q1 2025 Results Conference Call May 14, 2025 4:30 PM ET Company Participants Jon Patton - Director of Investor Relations and Communications Wayne Pisano - Chair of Oncolytics' Board of Directors and Interim Chief Executive Officer Dr. Tom Heineman - Chief Medical Officer Christophe Degois - Vice President of Business Development Kirk Look - Chief Financial Officer Conference Call Participants Patrick Trucchio - H.C. Wainwright Michael Freeman - Raymond James Operator Good afternoon, and welcome to Oncolytics Biotech First Quarter Conference Call.
Oncolytics Biotech Inc. (ONCY) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Oncolytics Biotech Inc. ever had a stock split?
Oncolytics Biotech Inc. Profile
| Biotechnology Industry | Healthcare Sector | Jared Kelly CEO | NASDAQ (CM) Exchange | 682310875 CUSIP |
| CA Country | 28 Employees | - Last Dividend | 25 May 2018 Last Split | - IPO Date |
Overview
Oncolytics Biotech Inc. operates within the cutting-edge field of biopharmaceuticals, dedicating its resources and expertise to the discovery and development of novel pharmaceutical treatments specifically targeting cancer. As a clinical-stage company, its primary focus revolves around advancing the research, development, and eventual commercialization of cancer therapeutics. The collaborative efforts with leading pharmaceutical entities such as Merck KGaA, Pfizer Inc., and Roche Holding AG further exemplify Oncolytics' commitment to leveraging partnerships to augment the development process of its key product candidates. Founded in 1998, Oncolytics has established its headquarters in Calgary, Canada, positioning itself at the forefront of cancer research innovation.
Products and Services
Pelareorep: Positioned as the cornerstone of Oncolytics Biotech's developmental portfolio, pelareorep is an intravenously delivered immunotherapeutic agent. Currently, it is undergoing a phase 3 clinical trial, demonstrating its potential efficacy against hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer. This product embodies the company's concerted effort to harness the power of the immune system in combating cancer, showcasing a novel approach to oncological treatment. Furthermore, pelareorep's application is being explored in the treatment of advanced/metastatic pancreatic ductal adenocarcinoma, signifying its versatility and the broad scope of its potential therapeutic impact.
Contact Information
